Back to Newsroom
Back to Newsroom

Black Bird Biotech Opens Grizzly Creek Naturals CBD Affiliate Sales Sign-up Portal Ahead of Sales Program Launch

Tuesday, 09 August 2022 08:55 AM

FLOWER MOUND, TX / ACCESSWIRE / August 9, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, announced the opening of a Sign-up Portal for its Affiliate Sales Program for its Grizzly Creek NaturalsTM CBD product line. Future Grizzly Creek NaturalsTM Affiliate Sales Reps can sign up at GrizzlyCreekAffiliates.com. The Company has scheduled the program launch for September 7, 2022.

"We ensure that our CBD products are of the highest quality and have been successful in maintaining a low-cost production capability, which has become extremely important in this period of significant inflation that has hit the supply chain especially hard," said Fabian Deneault, BBBT's President. "Our affiliate sales program is designed to minimize the impact of inflationary pressures on our end and, with a 20% sales commission structure, to maximize the reward for our Affiliates. As a guy that took on extra work to provide for his young family, I know that supplemental income from commissions that can offset the recent sudden increases in food and gas prices will be a welcomed opportunity," Mr. Deneault concluded.

According to an April 2022 report by Global Market Insights, the CBD market totaled $12.8 billion in 2021 and is expected to grow at a CAGR of 21.7% between 2022 and 2028. This expected growth is attributed to rising awareness of health benefits of CBD and its effectiveness in pain management and various other treatments. In addition, pet wellness is becoming a significant driver of CBD sales growth.

For news and updates, shareholders, prospective investors and prospective business partners are encouraged to follow @BBBT_Corporate on Twitter and @BlackBirdBiotech on Instagram. Also visit BBBT's corporate website, BlackBirdBiotech.com, for additional information about the company.

Black Bird Biotech, Inc., Tuesday, August 9, 2022, Press release picture

About BBBT

Black Bird Biotech is positioned to exploit market segments with powerful, re-imagined biotech products. Its EPA-registered biopesticide, MiteXstreamTM, eradicates mites and similar pests, including spider mites (a lethal pest in cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates molds and mildews. MiteXstreamTM is a pesticide, but it is not a poison - it's a pesticide re-imagined. The MiteXstreamTM Edge: use through the day of harvest without concern for residual "pesticide" violations, including as it pertains to state cannabis testing. MiteXstreamTM is the foundational element of the company that carries vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional "poisonous" pesticides.

Forward Looking Statements:

This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Eric Newlan
Vice President
833-223-4204
[email protected]
BlackBirdBiotech.com

SOURCE: Black Bird Biotech, Inc.

Topic:
Company Update
Back to newsroom
Back to Newsroom
Share by: